Jazz Pharmaceuticals up as Q3 results beat on both lines, adjusts 2025 guidance

 

• Jazz Pharmaceuticals (JAZZ) is up ~3% in after-hours trading Wednesday after reporting Q3 financial results that beat on both lines. The company also adjusted its full-year revenue guidance.
• The pharma now sees 2025 revenue of $4.175B-$4.275B from $4.15B-$4.3B prior. Consensus is $4.22B.
• In Q3, revenue increased 7.6% year-over-year, driven by sales of Epidiolex (cannabidiol) Xywav (calcium, magnesium, potassium & sodium oxybates), as well as the launch of Modeyso (dordaviprone). Xywav revenues were $302.6M (+20%), while Xywav's were $431.4M (+11%). Modeyso, which launched in August, brought in $11 M. 
• Jazz ended the quarter (Sept. 30) with cash, cash equivalents, and investments of ~$2B, compared to ~$3B on Dec. 31 ,2024 

https://www.msn.com/en-us/money/markets/jazz-pharmaceuticals-up-as-q3-results-beat-on-both-lines-adjusts-2025-guidance/ar-AA1PSQ25